After therapy, 18 patients were associated with a favorable prognosis, and two patients were ineffective with the treatment of neutral lipid storage myopathy (NLSDM) caused by PNPLA2 mutation. The gene discussed is PNPLA2; the disease is neutral lipid storage myopathy.